MX2012000956A - 1h-quinazolina-2,4-dionas para usarse en el tratamiento de lipofuscinosis ceroide neuronal. - Google Patents
1h-quinazolina-2,4-dionas para usarse en el tratamiento de lipofuscinosis ceroide neuronal.Info
- Publication number
- MX2012000956A MX2012000956A MX2012000956A MX2012000956A MX2012000956A MX 2012000956 A MX2012000956 A MX 2012000956A MX 2012000956 A MX2012000956 A MX 2012000956A MX 2012000956 A MX2012000956 A MX 2012000956A MX 2012000956 A MX2012000956 A MX 2012000956A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- diones
- quinazoline
- neuronal ceroid
- ceroid lipofuscinosis
- Prior art date
Links
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 title abstract 2
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 title abstract 2
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical class C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 title 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 abstract 1
- 239000000775 AMPA receptor antagonist Substances 0.000 abstract 1
- 230000002860 competitive effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22794009P | 2009-07-23 | 2009-07-23 | |
| PCT/EP2010/060733 WO2011009951A1 (en) | 2009-07-23 | 2010-07-23 | 1h-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012000956A true MX2012000956A (es) | 2012-02-28 |
Family
ID=42671655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012000956A MX2012000956A (es) | 2009-07-23 | 2010-07-23 | 1h-quinazolina-2,4-dionas para usarse en el tratamiento de lipofuscinosis ceroide neuronal. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120122903A1 (enExample) |
| EP (1) | EP2456442A1 (enExample) |
| JP (1) | JP2012533605A (enExample) |
| KR (1) | KR20120052341A (enExample) |
| CN (1) | CN102470137A (enExample) |
| AU (1) | AU2010274921B2 (enExample) |
| BR (1) | BR112012001258A2 (enExample) |
| CA (1) | CA2768333A1 (enExample) |
| IN (1) | IN2012DN00235A (enExample) |
| MX (1) | MX2012000956A (enExample) |
| RU (1) | RU2012106426A (enExample) |
| WO (1) | WO2011009951A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527807B2 (en) | 2011-04-05 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9400680D0 (en) * | 1994-01-14 | 1994-03-09 | Sandoz Ltd | Improvements in or relating to organic compounds |
| GB0416730D0 (en) * | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
| GB0507298D0 (en) * | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
-
2010
- 2010-07-23 CN CN2010800334750A patent/CN102470137A/zh active Pending
- 2010-07-23 BR BR112012001258A patent/BR112012001258A2/pt not_active IP Right Cessation
- 2010-07-23 MX MX2012000956A patent/MX2012000956A/es not_active Application Discontinuation
- 2010-07-23 RU RU2012106426/04A patent/RU2012106426A/ru not_active Application Discontinuation
- 2010-07-23 EP EP10734746A patent/EP2456442A1/en not_active Withdrawn
- 2010-07-23 JP JP2012521055A patent/JP2012533605A/ja active Pending
- 2010-07-23 WO PCT/EP2010/060733 patent/WO2011009951A1/en not_active Ceased
- 2010-07-23 KR KR1020127004575A patent/KR20120052341A/ko not_active Withdrawn
- 2010-07-23 CA CA2768333A patent/CA2768333A1/en not_active Abandoned
- 2010-07-23 US US13/384,280 patent/US20120122903A1/en not_active Abandoned
- 2010-07-23 IN IN235DEN2012 patent/IN2012DN00235A/en unknown
- 2010-07-23 AU AU2010274921A patent/AU2010274921B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012001258A2 (pt) | 2016-02-10 |
| JP2012533605A (ja) | 2012-12-27 |
| IN2012DN00235A (enExample) | 2015-05-01 |
| EP2456442A1 (en) | 2012-05-30 |
| KR20120052341A (ko) | 2012-05-23 |
| AU2010274921B2 (en) | 2014-08-14 |
| CA2768333A1 (en) | 2011-01-27 |
| CN102470137A (zh) | 2012-05-23 |
| RU2012106426A (ru) | 2013-08-27 |
| AU2010274921A1 (en) | 2012-02-02 |
| US20120122903A1 (en) | 2012-05-17 |
| WO2011009951A1 (en) | 2011-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253790A0 (en) | Factors in the treatment and/or prevention of autoimmune disease and the creation of regulatory t cells | |
| PL2349106T3 (pl) | System do leczenia męskiej dysfunkcji seksualnej | |
| IL206284A0 (en) | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions | |
| AP2011005672A0 (en) | Pyrazolopyrimidines and their use for the treatment of CNS disorders. | |
| TN2012000082A1 (en) | Use of nicotinic acetylcholine receptor alpha 7 activators | |
| IL205907A0 (en) | 14-3-3 antagonists for the prevention and treatment of arthritis | |
| MX2010007490A (es) | Preparacion de derivados de sulfamida. | |
| IN2012DN00572A (enExample) | ||
| WO2011009890A3 (en) | Use of azabicycloalkyl derivatives or pyrrolidine - 2 - one derivatives for the treatment or prevention of ataxia | |
| ZA201105986B (en) | Substituted pyrimidines for the treatment of cancer | |
| FR2951637B1 (fr) | Table pour massages de personnes allongees ou assises. | |
| MY150600A (en) | Use of opioid antagonists for treating urinary retention | |
| ZA201203808B (en) | Combination for the treatment of radiation-or chemotherapy-induced mucositis | |
| IL207397A0 (en) | Difluorobiphenylamide derivtives for the treatment of ocular hypertension | |
| EP2411042A4 (en) | Tissue kallikrein for the treatment of pancreatic cell dysfunction | |
| CL2008000091A1 (es) | Compuestos derivados de piridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del trastorno de agregacion plaquetaria. | |
| IL206881A0 (en) | Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy | |
| UA103468C2 (ru) | Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3 | |
| CL2012001606A1 (es) | Compuestos derivados de tiazoles bicíclicos como moduladores alostéricos de receptores mglur5; composición farmacéutica que los comprende; procedimiento de preparación de la composición farmacéutica; combinación farmacéutica; y uso del compuesto en la prevención, tratamiento o profilaxis de trastornos neurológicos o psiquiátricos. | |
| WO2007131041A3 (en) | The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2 | |
| MX2012000956A (es) | 1h-quinazolina-2,4-dionas para usarse en el tratamiento de lipofuscinosis ceroide neuronal. | |
| UA96574C2 (ru) | Использование ивабрадина для получения лекарств, предназначенных для лечения эндотелиальной дисфункции | |
| EP2284280A4 (en) | PRIMER, METHOD AND TOOL SET FOR DETERMINING THE FUNCTIONALITY OF HUMAN THYMUS | |
| MX2014002693A (es) | Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible. | |
| IL202506A0 (en) | Neramexane for the treatment of nystagmus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |